

74. Delayed-release formulation according to Claim 73, characterized in that the concentration of active principle is between 50 and 100%.

75. Delayed-release formulation according to Claim 73, characterized in that it has a thin and elongated form with a diameter not exceeding 3mm.

76. Delayed-release formulation according to Claim 75, characterized by a diameter not exceeding 2 mm.

77. Delayed-release formulation according to Claim 75, characterized by a diameter of the order of 0.1 mm.

78. Delayed-release formulation according to Claim 73, characterized by a minimum length/diameter ratio of 10.

79. Delayed-release formulation according to Claim 73, characterized in that it contains an active principle of peptide or protein nature.

80. Solid delayed-release formulation for parenteral administration comprising a homogeneous mixture of an active principle in the non-dispersed state forming a continuous phase of which at least one part is in direct contact with the exchange

21  
surface of the formulation and of the exterior biological medium, and of a biodegradable biocompatible excipient, in which the quantity of active principle is at least 50% by weight with respect to the total weight of the formulation, and having a release profile which is independent of the composition of the excipient, of the molecular weight of the excipient or of the active principle/excipient weight ratio, the release profile being essentially exclusively dependent on the total quantity of active principle present in the formulation.

81. Delayed-release formulation according to Claim 80, characterized in that the biodegradable biocompatible excipient is a polymer or copolymer of lactic and/or glycolic acid or a mixture of polymers and/or copolymers of lactic and/or glycolic acid.

82. Delayed-release formulation according to Claim 81, characterized in that the said biodegradable biocompatible polymer is a copolymer of lactic acid and glycolic acid (PLGA).

83. Delayed-release formulation according to Claim 80, characterized in that the said biodegradable biocompatible polymer is a copolymer of lactic and glycolic acid having an intrinsic viscosity in chloroform at 1 g per 100 ml of greater than 0.6 dl/g.

84. Delayed-release formulation according to Claim 82,

characterized in that the copolymer of lactic acid and glycolic acid is of hydrophilic nature.

85. Delayed-release formulation according to Claim 80, characterized in that, when it is placed *in vitro* in a physiological liquid medium, it liberates almost the whole of the active principle in less than a week, and, when it is placed *in vivo* subcutaneously or intramuscularly, has a release of active principle over a period substantially greater than one week.

86. Delayed-release formulation according to Claim 80, characterized in that it comprises a mixture of the active principle and the excipient which is homogenous at all points.

87. Delayed-release formulation according to Claim 80, characterized in that the release takes place in a single diffusion phase of the active principle.

88. Delayed-release formulation according to Claim 80, characterized in that the active principle represents at least 51%, advantageously at least 60%, preferably at least 70% and up to 99.999% by weight with respect to the total weight of the formulation, the excipient representing less than 50%, preferably less than 49%, and more advantageously less than 30% by weight with respect to the total weight of the formulation.

89. Delayed-release formulation according to Claim 80, characterized in that the active principle is a peptide, a peptide analogue or a protein, especially LHRH or an analogue of LHRH, especially Triptoreline.

90. Delayed-release formulation according to Claim 80, characterized in that it is in cylindrical form and has a diameter less than or equal to 3 mm, preferably less than 1 mm.

91. Delayed-release formulation according to Claim 80, for injection by the intramuscular or subcutaneous route.

92. Delayed-release formulation according to Claim 80, characterized in that it is in the form of an implant.

93. Process for preparation of a delayed-release formulation according to Claim 80, comprising the steps consisting in:

- producing a homogeneous mixture of the active principle and the excipient, containing at least 50% of active principle;
- compacting the said mixture; and
- extruding the said compacted mixture in the molten state.

94. Process for preparation of a formulation according to Claim 80, comprising the steps consisting in: